Your browser doesn't support javascript.
loading
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa, Luciano J; Chhabra, Saurabh; Medvedova, Eva; Dholaria, Bhagirathbhai R; Schmidt, Timothy M; Godby, Kelly N; Silbermann, Rebecca; Dhakal, Binod; Bal, Susan; Giri, Smith; D'Souza, Anita; Hall, Aric C; Hardwick, Pamela; Omel, James; Cornell, Robert F; Hari, Parameswaran; Callander, Natalie S.
Affiliation
  • Costa LJ; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: ljcosta@uabmc.edu.
  • Chhabra S; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Medvedova E; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
  • Dholaria BR; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Schmidt TM; Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisc onsin, Madison, WI, USA.
  • Godby KN; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Silbermann R; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
  • Dhakal B; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Bal S; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Giri S; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • D'Souza A; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Hall AC; Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisc onsin, Madison, WI, USA.
  • Hardwick P; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Omel J; Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT), Omaha, NE, USA.
  • Cornell RF; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Hari P; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Callander NS; Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisc onsin, Madison, WI, USA.
Lancet Haematol ; 10(11): e890-e901, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37776872
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Diagnostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Haematol Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Diagnostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Haematol Year: 2023 Document type: Article Country of publication: